How should NIH improve peer review?

Today, the NIH linkurl:announced;http://www.nih.gov/news/pr/jun2007/od-08.htm that it was establishing two working groups to examine its peer review process. That process has been under increased scrutiny recently, as study sections have needed to read more and more grant applications with every cycle. And with NIH funding flat, it's no longer good enough to be in the top 30% or so to get funded; in some study sections, it's close to 10%. So many scientists may find the examination welcome. In

Written byIvan Oransky
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Today, the NIH linkurl:announced;http://www.nih.gov/news/pr/jun2007/od-08.htm that it was establishing two working groups to examine its peer review process. That process has been under increased scrutiny recently, as study sections have needed to read more and more grant applications with every cycle. And with NIH funding flat, it's no longer good enough to be in the top 30% or so to get funded; in some study sections, it's close to 10%. So many scientists may find the examination welcome. In 2005, in the pages of The Scientist, David Kaplan linkurl:proposed;http://www.the-scientist.com/article/display/15701/ a number of ways to improve peer review at the NIH. What do you think of his suggestions, which include decreasing the length of the research plan to between two and four pages so that 20 to 30 reviews for each application could be solicited, and doing away with committee meetings? Where do you suggest the new committees look for improvements? Give us your ideas by linkurl:commenting;http://www.the-scientist.com/forum/addcomment/53276/ on this blog.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies